Published in Neurourol Urodyn on January 31, 2011
What predicts and what mediates the response of urge urinary incontinence to biofeedback? Neurourol Urodyn (2012) 2.05
Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome? World J Urol (2012) 0.80
Electroacupuncture at points Baliao and Huiyang (BL35) for post-stroke detrusor overactivity. Neural Regen Res (2013) 0.78
Management of lower urinary tract dysfunction in patients with neurological disorders. Korean J Urol (2012) 0.77
Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction. Int Braz J Urol (2016) 0.75
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn (2002) 8.01
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn (2004) 5.31
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol (2002) 4.31
Urodynamic features and artefacts. Neurourol Urodyn (2012) 3.78
Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int (2011) 3.28
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 2.58
The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 2.46
Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol (2008) 2.41
The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male non-neurogenic incontinence. Eur Urol (2012) 2.37
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol (2009) 2.33
A new classification is needed for pelvic pain syndromes--are existing terminologies of spurious diagnostic authority bad for patients? J Urol (2006) 2.13
EAU guidelines on urinary incontinence. Eur Urol (2010) 2.10
The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement. Eur Urol (2007) 2.03
The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol (2013) 1.87
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 2: Noninvasive urodynamics and combination of measures. J Urol (2006) 1.77
The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol (2006) 1.77
How should patients with an overactive bladder manipulate their fluid intake? BJU Int (2008) 1.70
Ultrasound estimated bladder weight and measurement of bladder wall thickness--useful noninvasive methods for assessing the lower urinary tract? J Urol (2010) 1.67
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
Noninvasive techniques for the measurement of isovolumetric bladder pressure. J Urol (2004) 1.58
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Risk of tape-related complications after TVT is at least 4%. Neurourol Urodyn (2010) 1.52
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int (2006) 1.50
The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG (2002) 1.50
Validity of the international consultation on incontinence questionnaire-pediatric lower urinary tract symptoms: a screening questionnaire for children. J Urol (2010) 1.48
A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle. J Pharmacol Exp Ther (2013) 1.47
The role of invasive and non-invasive urodynamics in male voiding lower urinary tract symptoms. World J Urol (2009) 1.46
Automatic evaluation of ultrasonography-estimated bladder weight and bladder wall thickness in community-dwelling men with presumably normal bladder function. BJU Int (2011) 1.45
Can maximum urethral closure pressure (MUCP) be used to predict outcome of surgical treatment of stress urinary incontinence? Neurourol Urodyn (2011) 1.44
What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial. Int Urogynecol J (2011) 1.41
Flow meter urine testing: a practical proposition in patients attending for urodynamics? BJU Int (2006) 1.40
The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Eur J Obstet Gynecol Reprod Biol (2011) 1.39
Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn (2008) 1.26
Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG (2004) 1.24
Overactive bladder and painful bladder syndrome: there need not be confusion. Neurourol Urodyn (2005) 1.23
A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. Am J Obstet Gynecol (2004) 1.23
Surgical treatment of stress incontinence in men. Neurourol Urodyn (2010) 1.23
Urogenital pain--time to accept a new approach to phenotyping and, as a consequence, management. Eur Urol (2007) 1.19
Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int (2008) 1.12
Overactive bladder: an update. Curr Opin Urol (2007) 1.08
Editorial comment: Re: Brubaker L. Conflict of interest: what is the role of our professional societies? Neurourol Urodyn 2012;31:1217-1218. Neurourol Urodyn (2012) 1.08
Animal models in overactive bladder research. Handb Exp Pharmacol (2011) 1.07
Development and validation of a quality-of-life measure for men with nocturia. Urology (2004) 1.07
Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ (2002) 1.06
Access to every trial dataset is crucial. BMJ (2004) 1.06
Suprapubic catheter insertion is an outpatient procedure: cost savings resultant on closing an audit loop. BJU Int (2008) 1.05
The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol (2005) 1.03
Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: Nonurodynamic approach. J Urol (2006) 1.03
The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int (2005) 1.00
Technique of urethral retro-resistance pressure measurement. Neurourol Urodyn (2004) 1.00
Interstitial cells and phasic activity in the isolated mouse bladder. BJU Int (2006) 0.98
Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int (2006) 0.97
Nocturia as a manifestation of systemic disease. BJU Int (2011) 0.97
Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med (2008) 0.95
What are the causes and consequences of bladder overdistension? ICI-RS 2011. Neurourol Urodyn (2012) 0.95
Persistent detrusor overactivity after transurethral resection of the prostate. Curr Urol Rep (2008) 0.95
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs (2004) 0.94
The extent and severity of urinary incontinence amongst women in UK GP waiting rooms. Fam Pract (2006) 0.93
Botulinum toxin treatment for overactive bladder: risk of urinary retention. Curr Urol Rep (2008) 0.93
Etiology and management of urinary retention in women. Indian J Urol (2010) 0.92
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int (2006) 0.92
Can we prevent incontinence? ICI-RS 2011. Neurourol Urodyn (2012) 0.91
A patient-centered approach to developing a comprehensive symptom and quality of life assessment of anal incontinence. Dis Colon Rectum (2007) 0.90
The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol (2003) 0.90
Benign prostatic hyperplasia: The term BPH is misused. BMJ (2008) 0.89
Natural history of detrusor contractility--minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. Scand J Urol Nephrol Suppl (2004) 0.89
Psychometric evaluation of a new patient-completed questionnaire for evaluating anal incontinence symptoms and impact on quality of life: the ICIQ-B. Dis Colon Rectum (2011) 0.88
Cure sometimes, help always--a "continence paradigm" for all ages and conditions. Neurourol Urodyn (2006) 0.88
Does the patient's position influence the detection of detrusor overactivity? Neurourol Urodyn (2008) 0.88
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol (2006) 0.86
Nocturnal enuresis with antipsychotic medication. Br J Psychiatry (2012) 0.85
Bladder outlet physiology in the context of lower urinary tract dysfunction. Neurourol Urodyn (2011) 0.85
The 50-year history of the ice water test in urology. J Urol (2010) 0.85
Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn (2008) 0.85
Volume-induced effects on the isolated bladder: a possible local reflex. BJU Int (2004) 0.85
Management of overactive bladder. Nat Rev Urol (2010) 0.85
The medical management of urinary incontinence. Auton Neurosci (2009) 0.84
The validation of a functional, isolated pig bladder model for physiological experimentation. Front Pharmacol (2012) 0.84
Developing evidence-based standards for diagnosis and management of lower urinary tract or pelvic floor dysfunction. Neurourol Urodyn (2012) 0.84
An exploration of the control of micturition using a novel in situ arterially perfused rat preparation. Front Neurosci (2011) 0.83
Defining achievable standards in urodynamics-a prospective study of initial resting pressures. Neurourol Urodyn (2012) 0.83
Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol (2002) 0.83
Impact of surgical treatment on nocturia in men with benign prostatic obstruction. BJU Int (2006) 0.83
Recognition and effective management of autonomic dysreflexia in spinal cord injuries. Expert Opin Pharmacother (2007) 0.83
Success rates for learning intermittent self-catheterisation according to age and gender. Int Urol Nephrol (2012) 0.83
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int (2014) 0.82
Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome. Neurourol Urodyn (2009) 0.82
The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated detrusor underactivity. BJU Int (2005) 0.81
Nocturia: new directions. Neurourol Urodyn (2011) 0.81
Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction. Cochrane Database Syst Rev (2015) 0.81